Ipsen

Ipsen Long-term Debt

The Long-Term Debt of Ipsen (IPN.PA) as of Nov 6, 2026 is 748.20 M EUR. In the previous year, Long-Term Debt was 287.50 M EUR — a change of 160.24% (higher).

Long-term Debt

748.20 MEUR

YoY

160.24%

Last updated:

Long-Term Debt of Ipsen is 2025 748.20 M EUR. Long-Term Debt of Ipsen was 2024 287.50 M EUR. It decreases by 160.24% higher compared to the previous year.

The Ipsen Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2018
297.90 M EUR
Jan 1, 2019
696.30 M EUR
Jan 1, 2020
639.10 M EUR
Jan 1, 2021
772.20 M EUR
Jan 1, 2022
667.00 M EUR
Jan 1, 2023
337.10 M EUR
Jan 1, 2024
287.50 M EUR
Jan 1, 2025
748.20 M EUR
The Ipsen Long-term Debt history
YEARLong-term DebtYoY
748.20 MEUR+160.24%
287.50 MEUR-14.71%
337.10 MEUR-49.46%
667.00 MEUR-13.62%
772.20 MEUR+20.83%
639.10 MEUR-8.21%
696.30 MEUR+133.74%
297.90 MEUR+0.13%
297.50 MEUR+0.13%
297.10 MEUR+1,342.23%
20.60 MEUR+70.25%
12.10 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ipsen Stock analysis

What does Ipsen do? Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ipsen stock

Long-Term Debt of Ipsen is 748.20 M EUR in 2025.

Long-Term Debt of Ipsen changed from 287.50 M EUR to 748.20 M EUR, representing a 160.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Ipsen since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Ipsen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Ipsen

All Key Metrics — Ipsen